Author:
T.A. Voronina, E.A. Ivanova
FGBNU "Research Institute of Pharmacology named after V.V. Zakusova ”, Moscow, Russia
Author:
T.A. Voronina, E.A. Ivanova
FGBNU "Research Institute of Pharmacology named after V.V. Zakusova ”, Moscow, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY STROKE No. 4/2019
Abstract:
This review presents data on the combined use of Mexidol with drugs from various pharmacotherapeutic groups. Mexidol, with its multimodal mechanism of action and broad spectrum of pharmacological effects, enhances the primary action of drugs both experimentally and clinically, increases the effectiveness of therapy prescribed to patients in accordance with current federal standards, and helps reduce the severity of disease complications. The data presented in the review on the efficacy and pathogenetic validity of combination therapy with Mexidol and other drugs demonstrate the feasibility of this approach for the treatment of cerebrovascular and cardiovascular diseases, diseases of the nervous system, open-angle glaucoma, alcohol intoxication, and a number of other conditions. Key words: Mexidol, combination therapy, free radicals, lipid peroxidation, ischemic stroke, myocardial infarction, ischemic heart disease, epilepsy, glaucoma, alcohol intoxication.
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com